Scott Rockledge the Managing Partner of 5AM Ventures champions the fight to cure myotonic dystrophy type 1. Scott Rockledge earned his Bachelor of Science degree in Chemistry from the University of California Berkeley and also received his Ph.D. in Chemistry from the Massachusetts Institute of Technology.
Dr. Rockledge has more than 30 years of experience in Healthcare Management and has pioneered the FDA approval of 3 medications Cubicin, Teslascan, and Omniscan were approved clinical trials and released to the public. In his career Scott Rockledge a valuable part of the creation of more than 30 US Patents that he either invented or co-invented.
With this vast experience in the medical research industry, Dr. Rockledge has separated himself as a leader and pioneer in the industry of healthcare innovation. He has established himself as a renowned scientist and persistent investor in research and development for cures for some of our society’s most devastating diseases.
As a Managing Partner at 5AM Ventures, Scott has partnered with the company Expansion Therapeutics to raise 55.3 million dollars to assist in the fight against myotonic dystrophy. Myopic dystrophy symptoms are believed to present themselves when RNA reaches toxic levels and these molecules are then transferred from DNA and converted into proteins.
Dr. Rockledge has pioneered efforts through research, new ideas and patterns of thinking that will lead to the eradication of the symptoms of myotonic dystrophy.
With a documented desire for medical research for cures, Scott Rockledge is establishing himself as both a renowned scientist and innovative Healthcare Management manager that discovers new and creative approaches and systematic processes to eliminate and eradicate diseases like myotonic dystrophy and many other perplexing diseases in our society.
He is surrounding himself with the leaders in the industry of medical research to assist in the fight against these diseases.
Scott Rockledge has established a track record of successful results, patents and other trending edge technologies and prescriptions as managing partner at 5AM Ventures and is continuing to champion the fight for a swift cure for myotonic dystrophy.